Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 7
2004 2
2005 4
2006 1
2007 4
2008 4
2009 5
2010 3
2011 2
2012 8
2013 6
2014 5
2015 2
2016 3
2017 2
2018 3
2019 2
2020 2
2021 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.
Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Sperling RA, et al. Among authors: grundman m. Alzheimers Dement. 2011 Jul;7(4):367-85. doi: 10.1016/j.jalz.2011.05.2351. Alzheimers Dement. 2011. PMID: 21784348 Free PMC article. Review.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. Among authors: grundman m. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Waybright L, Look G, Rishton G, Safferstein H, Hamby ME, Williams C, Sadlek K, Edwards HM, Davis CS, Grundman M, Schneider LS, DeKosky ST, Chelsky D, Pike I, Henstridge C, Blennow K, Zetterberg H, LeVine H 3rd, Spires-Jones TL, Cirrito JR, Catalano SM. Izzo NJ, et al. Among authors: grundman m. Alzheimers Dement. 2021 Aug;17(8):1365-1382. doi: 10.1002/alz.12302. Epub 2021 Feb 8. Alzheimers Dement. 2021. PMID: 33559354 Free PMC article. Clinical Trial.
Value-Generating Exploratory Trials in Neurodegenerative Dementias.
Friedman LG, McKeehan N, Hara Y, Cummings JL, Matthews DC, Zhu J, Mohs RC, Wang D, Hendrix SB, Quintana M, Schneider LS, Grundman M, Dickson SP, Feldman HH, Jaeger J, Finger EC, Ryan JM, Niehoff D, Dickinson SL, Markowitz JT, Owen M, Travaglia A, Fillit HM. Friedman LG, et al. Among authors: grundman m. Neurology. 2021 May 18;96(20):944-954. doi: 10.1212/WNL.0000000000011774. Epub 2021 Mar 5. Neurology. 2021. PMID: 33674360 Free PMC article. Review.
NSAIDs and hypertension.
Aisen PS, Schafer K, Grundman M, Thomas R, Thal LJ. Aisen PS, et al. Among authors: grundman m. Arch Intern Med. 2003 May 12;163(9):1115; author reply 1115-6. doi: 10.1001/archinte.163.9.1115-a. Arch Intern Med. 2003. PMID: 12742818 No abstract available.
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O'Gorman J, Haeberlein SB; PASSPORT Study Group. Dam T, et al. Among authors: grundman m. Nat Med. 2021 Aug;27(8):1451-1457. doi: 10.1038/s41591-021-01455-x. Epub 2021 Aug 12. Nat Med. 2021. PMID: 34385707 Clinical Trial.
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter.
LaBarbera KM, Sheline YI, Izzo NJ, Yuede CM, Waybright L, Yurko R, Edwards HM, Gardiner WD, Blennow K, Zetterberg H, Börjesson-Hanson A, Morgan R, Davis CS, Guttendorf RJ, Schneider LS, DeKosky S, LeVine H 3rd, Grundman M, Caggiano AO, Cirrito JR, Catalano SM, Hamby ME. LaBarbera KM, et al. Among authors: grundman m. Transl Neurodegener. 2023 May 12;12(1):24. doi: 10.1186/s40035-023-00358-w. Transl Neurodegener. 2023. PMID: 37173791 Free PMC article. Clinical Trial. No abstract available.
68 results